Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

PI-103

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

mTOR inhibitor, PI3K inhibitor

Related drugs:

‹

everolimus (138)

temsirolimus (37)

PF-05212384 (31)

GSK2126458 (17)

PF-04691502 (6)

niclosamide (1)

rapamycin topical (0)

ridaforolimus (0)

encapsulated rapamycin (0)

inhibitors of the PI3K/AKT/mTOR pathway (0)

albumin-bound (0)

enzastaurin (3)

BAY 1082439 (1)

›

KRAS mutation	Multiple Myeloma	KRAS mutation	Multiple Myeloma	CI-1040 + PI-103 Sensitive: D – Preclinical CI-1040 + PI-103 Sensitive : D	CI-1040 + PI-103 Sensitive: D – Preclinical CI-1040 + PI-103 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	palbociclib + AZD1775 + PI-103 Sensitive: D – Preclinical palbociclib + AZD1775 + PI-103 Sensitive : D	palbociclib + AZD1775 + PI-103 Sensitive: D – Preclinical palbociclib + AZD1775 + PI-103 Sensitive : D